期刊文献+

胰腺癌化疗:替吉奥与吉西他滨的应用及展望 被引量:5

原文传递
导出
摘要 胰腺癌是高度恶性的消化系统肿瘤,死亡率居恶性肿瘤第4位,总体5年生存率仅5%。手术是目前治疗的唯一有效手段,但超过80%的患者在确诊时已处于进展期而无法手术切除;即使行根治性手术,仍有高局部复发率及远处转移率。如何选择更有效的化疗药物使胰腺癌患者从中获益,一直是辅助化疗研究和争论的焦点问题。
作者 苏维宏 孙备
出处 《中华胰腺病杂志》 CAS 2014年第1期69-72,共4页 Chinese Journal of Pancreatology
基金 国家自然科学基金资助项目(81170431,81372613,81370565) 卫生公益性行业科研专项经费资助项目(201202007) 高等学校博士学科点专项基金(20122307110012)
  • 相关文献

参考文献30

  • 1Gillen S,Schuster T,Friess H. Preoperative/neoadjuvant therapy in pancreatic cancer:a systematic review and metaanalysis of response and resection percentages[J].PLOS MEDICINE,2010,(04):e1000267.
  • 2Nakamura K,Yamaguchi T,Ishihara T. Phase Ⅰ trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer[J].British Journal of Cancer,2005,(12):2134-2139.
  • 3Tajima H,Ohta T,Kitagawa H. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer[J].Exp Ther Med,2012.787-792.
  • 4Motoi F,Ishida K,Fujishima F. Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma:Results from a Prospective Multi-institutional Phase 2 Trial[J].ANNALS OF SURGICAL ONCOLOGY,2013,(12):3794-3801.
  • 5Ueno H,Okusaka T,Ikcda M. A phase Ⅰ study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer[J].ONCOLOGY-BASEL,2005,(05):421-427.
  • 6Nakamura K,Yamaguchi T,Ishihara T. Phase Ⅱ trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer[J].British Journal of Cancer,2006,(11):1575-1579.
  • 7Lee GW,Kim HJ,Ju JH. Phase Ⅱ trial of S-1 in combination with gemcitabine for chemo-naive patients with locally advanced or metastatic pancreatic cancer[J].Cancer Chemother Phannacol,2009,(04):707-713.
  • 8Heinemann V,Boeck S,Hinke A. Meta-analysis of randomized trials:evaluation of benefit from gemcitabine based combination chemotherapy applied in advanced pancreatic cancer[J].BMC Cancer,2008.82.
  • 9Sultana A,Smith CT,Cunningham D. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer[J].Journal of Clinical Oncology,2007,(18):2607-2615.
  • 10Nakai Y,Isayama H,Sasaki T. Impact of S-1 on the survival of patients with advanced pancreatic cancer[J].PANCREAS,2010,(07):989-993.

二级参考文献26

  • 1Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single- institution experience [J]. J Gastrointest Surg, 2006, 10 ( 9 ) : 1199 -1211.
  • 2Farnell MB, Pearson RK, Sarr MG, et al. Pancreas Cancer Working Group. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma [ J]. Surgery, 2005, 138 (4) : 618 - 630.
  • 3Yoshiaki M, Kenichiro U, Takeshi S, et al. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma [ J ]. Am J Surg, 2008, 195 (6) :757 -762.
  • 4Yoshiaki M, Kenichiro U, Takeshi S, et al. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas[J].J Gastrointest Surg ,2009,13 (1):85 -92.
  • 5Nakai Y, Isayama H, Sasaki T, et al. A multicenter randomized controlled trial of gemcitabine ( G ) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer ( PC ) : GEMSAP study[J]. J Clin Oncol,2010,28(15 Suppl) :4037.
  • 6Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009 [J]. CA Cancer J Clin,2009,59(4) :225 -249.
  • 7Homma H, Doi T, Mezawa S, et al. A novel arterial infusion chemotherapy for treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superse- lective embolizatiou [ J ]. Cancer, 2000,89 ( 2 ) : 303 - 313.
  • 8Ueno H, Okusaka T, Ikeda M, et al. Phase II study of S- 1 in patients with advanced biliary tract cancer [ J ]. Br J Cancer,2004,91 (10) : 1769 - t674.
  • 9Neoptolemos JP, Stocken DD, Friess H, et al. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J]. N Engl J Med,2004,350(12) : 1200 - 1210.
  • 10Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial [ J ]. JAMA, 2007,297 ( 3 ) : 267 - 277.

共引文献23

同被引文献51

  • 1陈东升,吴光兴,唐丽珠.胰腺癌根治术后行吉西他滨联合替吉奥化疗的临床观察[J].实用癌症杂志,2014,29(1):78-80. 被引量:19
  • 2王三妹,陈宝安.胰腺癌的细胞治疗新进展[J].中国肿瘤生物治疗杂志,2015,22(3):369-374. 被引量:5
  • 3许慎,蔡友鹏,甘立菁,詹丽芬,林淑君.吉西他滨治疗晚期恶性肿瘤的临床观察[J].中国肿瘤,2005,14(7):481-482. 被引量:1
  • 4赵玉沛.胰腺癌诊治指南[J].中国实用外科杂志,2007,27(9):671-673. 被引量:48
  • 5Schiller JH, Harrington D, Belani CP, et al. Compariosn of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med,2002,346(2) :92 -98.
  • 6Bhatia M, Davenport V, Cario MS. The role of interleukin- 11 to prevent chemotheraphy-indueed thrombocytopenia in patients with solid tumors lymphoma, acute myeloid leukemia and bone marrow failure syndromes [ J]. Leuk lymphoma, 2007,48 ( 1 ) :9 - 15.
  • 7Tsimberidon AM, Giles FJ, Khouri I, et al. Low-dose interleukin- 11 in patients with bone marrow failure:update of the M. D. An- derson Cancer Lonter experience [ J ]. Am Oneol, 2005,16 ( 1 ) : 139 - 145.
  • 8Carlo MS, Davenport V, Bessmertny O, et al. Phase 1 / II dose escalation study of recombinant human interleukin- 11 following if- osfamide, carboplatin and eloposide in children, adolescents and young adults with solid tumors lymphoma : a clinical, haematological and biological study[ J]. Br J Haematol,2005,128( 1 ) :49 -58.
  • 9Sharma RA, Steward WP, Geseher AJ. Pharmacokineties and pharmaeodynamies of cureumin [ J ]. Adv Exp Med Biol, 2007, 595:453 - 470.
  • 10Safavy A, Raiseh KP, Mantena S, et al. Design and development of water-soluble curcumin conjugates as potential antieaneer agents [J]. J Med Chen, 2007, 50(24) :6284 -6288.

引证文献5

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部